Ignacio I Wistuba

Summary

Publications

  1. pmc Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer
    Ludmila Prudkin
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 14:41-7. 2008
  2. ncbi Lung cancer preneoplasia
    Ignacio I Wistuba
    Department of Pathology, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    Annu Rev Pathol 1:331-48. 2006
  3. pmc Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung
    Ludmila Prudkin
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Mod Pathol 22:668-78. 2009
  4. pmc Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
    Pierre Saintigny
    Department of 1Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 5The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA
    Mol Cancer Ther 11:2021-32. 2012
  5. pmc Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy
    Apar Pataer
    Departments of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:825-32. 2012
  6. pmc An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Lauren Averett Byers
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:279-90. 2013
  7. pmc G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer
    Junya Fujimoto
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Thorac Oncol 7:1747-54. 2012
  8. pmc Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis
    Ximing Tang
    Departmentsof Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:2434-43. 2011
  9. pmc Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas
    Ximing Tang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Prev Res (Phila) 1:192-200. 2008
  10. pmc Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells
    Jie Zhang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Prev Res (Phila) 1:201-7. 2008

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. pmc Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer
    Ludmila Prudkin
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 14:41-7. 2008
    ..However, the expression of Fus1 protein has not been examined in a large series of lung cancers and their sequential preneoplastic lesions...
  2. ncbi Lung cancer preneoplasia
    Ignacio I Wistuba
    Department of Pathology, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    Annu Rev Pathol 1:331-48. 2006
    ....
  3. pmc Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung
    Ludmila Prudkin
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Mod Pathol 22:668-78. 2009
    ..Brain metastases showed characteristics of reversed mesenchymal-to-epithelial transition. Our findings suggest that epithelial-to-mesenchymal transition is a potential target for lung cancer chemoprevention and therapy...
  4. pmc Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
    Pierre Saintigny
    Department of 1Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 5The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA
    Mol Cancer Ther 11:2021-32. 2012
    ..EphA4 gene expression is associated with an improved outcome in patients with resected lung adenocarcinoma, possibly by affecting cancer cell migration and invasion...
  5. pmc Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy
    Apar Pataer
    Departments of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:825-32. 2012
    ....
  6. pmc An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Lauren Averett Byers
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:279-90. 2013
    ....
  7. pmc G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer
    Junya Fujimoto
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Thorac Oncol 7:1747-54. 2012
    ..The implication of GPRC5A in human lung cancer pathogenesis, including that associated with inflammatory chronic obstructive pulmonary disease (COPD), a risk factor for the malignancy, remains elusive...
  8. pmc Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis
    Ximing Tang
    Departmentsof Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:2434-43. 2011
    ..The thyroid transcription factor 1 (TITF-1) gene functions as a lineage survival gene abnormally expressed in a significant fraction of non-small cell lung cancers (NSCLC), in particular lung adenocarcinomas...
  9. pmc Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas
    Ximing Tang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Prev Res (Phila) 1:192-200. 2008
    ..Our findings have important implications for the development of new strategies for targeted chemoprevention and therapy in lung adenocarcinoma using EGFR inhibitors...
  10. pmc Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells
    Jie Zhang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Prev Res (Phila) 1:201-7. 2008
    ....
  11. ncbi Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S13-9. 2006
    ..Advances in the pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC) have demonstrated important new prognostic features that have led to changes in classification and diagnostic criteria...
  12. pmc Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions
    Carmen Behrens
    Departmentsof Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 16:34-44. 2010
    ..To identify the pattern of interleukin-1 receptor-associated kinase (IRAK-1) protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions...
  13. doi Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases
    Luisa M Solis
    Departments of Pathology, Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 133:133-40. 2010
    ..These cases represent an unusual variant of pulmonary adenocarcinoma...
  14. pmc Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC
    Chengcheng Guo
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Thorac Oncol 8:301-8. 2013
    ....
  15. pmc Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model
    Seyed Javad Moghaddam
    Department of Pulmonary Medicine, University of Texas M D Anderson Cancer Center, 2121 W Holcombe Boulevard, Suite 703F, Houston, TX 77030, USA
    Am J Respir Cell Mol Biol 40:443-53. 2009
    ..We conclude that COPD-like airway inflammation promotes lung carcinogenesis in a background of a G12D-activated K-ras allele in airway secretory cells...
  16. pmc Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung
    Ping Yuan
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e9112. 2010
    ..The sequential pathogenesis of lung adenocarcinomas and SCCs occurs through dissimilar phases as the former tumors typically arise in the lung periphery whereas the latter normally arise near the central airway...
  17. pmc ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer
    Mohamed Kabbout
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
    Clin Cancer Res 19:3383-95. 2013
    ..In this study, we probed the yet unknown functional role of ETS2 in lung cancer pathogenesis...
  18. pmc A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis
    Humam Kadara
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:1490-501. 2011
    ..Here, we assessed in NSCLC the prognostic efficacy of genes, which we had previously found to be differentially expressed in an in vitro model of human lung carcinogenesis...
  19. pmc Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression
    Young Ho Ahn
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cell Biol 31:4270-85. 2011
    ..We conclude that Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing PPARγ2 levels...
  20. pmc Tissue platinum concentration and tumor response in non-small-cell lung cancer
    Eric S Kim
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA
    J Clin Oncol 30:3345-52. 2012
    ..We assessed the effects of tissue platinum concentrations on response and survival in NSCLC...
  21. pmc High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation
    Maria Ines Nunez
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:833-40. 2012
    ..Information on the protein expression of these receptors in non-small-cell lung carcinoma (NSCLC) is limited...
  22. pmc Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome
    Luisa M Solis
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2889-99. 2012
    ..Lung adenocarcinoma is histologically heterogeneous and has 5 distinct histologic growth patterns: lepidic, acinar, papillary, micropapillary, and solid. To date, there is no consensus regarding the clinical utility of these patterns...
  23. pmc Biological activity of celecoxib in the bronchial epithelium of current and former smokers
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 3:148-59. 2010
    ..Celecoxib (400 mg twice daily) was biologically active in the bronchial epithelium of current and former smokers; additional studies on the efficacy of celecoxib in non-small cell lung cancer chemoprevention may be warranted...
  24. pmc HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors
    Menghong Sun
    Departments of Pathology, Thoracic Head and Neck Medical Oncology, Biostatistics, and Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Cancer Res 15:4829-37. 2009
    ..To compare the characteristics of deregulation of HER receptors and their ligands between primary tumor and corresponding brain metastases of non-small cell lung carcinoma (NSCLC)...
  25. pmc Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system
    Humam Kadara
    Departments of Thoracic Head and Neck MedicalOncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:702-11. 2009
    ..Moreover, one of those genes, UBE2C, seems to be a powerful biomarker for NSCLC survival prediction...
  26. pmc Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors
    Woo Young Kim
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:3993-4003. 2012
    ..The authors investigated the involvement of insulinlike growth factor 1 receptor (IGF-1R) signaling in primary resistance to EGFR TKIs and the molecular determinants of resistance to IGF-1R TKIs...
  27. doi Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:2104-11. 2011
    ..Baseline tumor specimens, serum, and perfusion computed tomography (CT) scans were obtained for supportive evaluation...
  28. pmc Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer
    Anne S Tsao
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 12:369-74. 2011
    ..Further studies are warranted to determine whether PDGFR-b is a feasible therapeutic target in this population...
  29. pmc Mortality in the randomized, controlled lung intergroup trial of isotretinoin
    J Jack Lee
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    Cancer Prev Res (Phila) 3:738-44. 2010
    ..The overall indications of this study have public health implications for treating acne in young people and other uses of retinoids in smokers...
  30. pmc SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines
    Jie Zhang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Pathol 170:366-76. 2007
    ..We conclude that SFKs are activated in NSCLC biopsy samples, promote the survival of EGFR-dependent NSCLC cells, and should be investigated as therapeutic targets in NSCLC patients...
  31. pmc Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer
    Kentaro Iwanaga
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:1119-27. 2008
    ..Thus, Pten inactivation cooperated with oncogenic K-ras in promoting lung tumorigenesis...
  32. pmc Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling
    Humam Kadara
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:8-17. 2013
    ..03). This study highlights spatial and temporal cancer-associated expression alterations in the molecular field of injury of patients with early-stage NSCLCs after definitive surgery that warrant further validation in independent studies...
  33. pmc CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma
    Pierre Saintigny
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 73:571-82. 2013
    ..Expression of CXCL5 was regulated by promoter methylation. The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma...
  34. doi HER family receptor and ligand status in thymic carcinoma
    Annikka Weissferdt
    Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 77:515-21. 2012
    ....
  35. pmc Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation
    Maria G Raso
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 15:5359-68. 2009
    ....
  36. doi Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer
    Carmen Behrens
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:6014-22. 2008
    ....
  37. pmc Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection
    Min P Kim
    Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 92:1044-50. 2011
    ....
  38. ncbi KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:2890-6. 2007
    ..In contrast, KRAS mutation has been shown to predict poor response to such therapy. We tested the utility of combinations of these three markers in predicting response and survival in patients with NSCLC treated with EGFR-TKIs...
  39. ncbi High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor
    Nobukazu Fujimoto
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Res 65:11478-85. 2005
    ..Thus, lung adenocarcinoma cells that depend on EGFR for survival constitutively activate the receptor through a combination of genetic mutations and overexpression of EGFR dimeric partners and their ligands...
  40. pmc Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method
    Seung Wook Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Res 67:6565-73. 2007
    ..These ASF proteins may be used to detect abnormal lesions in the lung without collecting invasive biopsy specimens...
  41. pmc Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial
    Alda L Tam
    Department of Diagnostic Radiology, Unit 1471, The University of Texas, M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230, USA
    J Thorac Oncol 8:436-42. 2013
    ....
  42. pmc Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
    Osamu Takahashi
    Department of Radiation Oncology The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:1641-54. 2012
    ....
  43. pmc Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer
    Jin Soo Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:2454-65. 2012
    ..The purpose of this study was to characterize insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF-1R) expression in patients with nonsmall cell lung cancer (NSCLC)...
  44. pmc Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung
    J Matthew McDonald
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7832-7. 2008
    ..The primary objective of this study was to determine whether markers of differentiation and activation of the Akt pathway are associated with metastasis in adenocarcinoma of the lung...
  45. pmc Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients
    Abujiang Pataer
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:5522-8. 2010
    ..To explore the role of PKR in human lung cancer, we evaluated the expression of PKR in tissue microarray (TMA) specimens from both non-small cell lung cancer (NSCLC) and normal human bronchial epithelium tissue...
  46. pmc Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features
    Luisa M Solis
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:3743-53. 2010
    ....
  47. pmc Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
    Lauren Averett Byers
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Discov 2:798-811. 2012
    ..On the basis of these results, clinical studies evaluating PARP and EZH2 inhibition, together with chemotherapy or other agents, warrant further investigation...
  48. ncbi The BATTLE trial: personalizing therapy for lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 1:44-53. 2011
    ..BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials...
  49. ncbi A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck
    Carol M Lewis
    Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:1435-46. 2012
    ..To determine the disease control rate and toxicity of treating patients with aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib...
  50. pmc Pulmonary adenocarcinoma: a renewed entity in 2011
    Humam Kadara
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Respirology 17:50-65. 2012
    ....
  51. doi Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung
    Koji Tsuta
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Lung Cancer 71:34-41. 2011
    ....
  52. pmc Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene
    Narayan Shivapurkar
    Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer Res 68:7448-56. 2008
    ..Our data constitute the first direct functional evidence for CYGB, the newest member of the globin family, as a tumor suppressor gene...
  53. ncbi Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin
    Quanri Jin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:11630-9. 2007
    ....
  54. ncbi Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers
    Maria Gabriela Raso
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Thorac Oncol 2:S128-35. 2007
    ..This study offers the opportunity to prospectively obtain, bank, and analyze tissue and other clinical specimens, which should facilitate the identification of new biomarkers for early detection, prognosis, and therapy in lung cancer...
  55. pmc Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
    Eric S Kim
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA Electronic address
    Lung Cancer 85:88-93. 2014
    ..We investigated the relationship between tissue platinum concentrations and CTR1 expression in NSCLC specimens...
  56. pmc Fibulin-2 is a driver of malignant progression in lung adenocarcinoma
    Brandi N Baird
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e67054. 2013
    ..We conclude that fibulin-2 is a driver of malignant progression in lung adenocarcinoma and plays an unexpected role in collagen cross-linking and tumor cell adherence to collagen...
  57. ncbi Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras
    Marie Wislez
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 65:3226-35. 2005
    ....
  58. ncbi EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients
    Ximing Tang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 65:7568-72. 2005
    ..Our findings indicate that mutation of the tyrosine kinase domain of EGFR is an early event in the pathogenesis of lung adenocarcinomas, and suggest EGFR mutations as an early detection marker and chemoprevention target...
  59. pmc Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy
    Fei Yang
    Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 71:5512-21. 2011
    ....
  60. ncbi Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions
    Ximing Tang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2637-46. 2006
    ..Although NF-kappaB can be activated in lung cancer cell lines by tobacco exposure, there have been no studies of the expression of NF-kappaB in lung cancer pathogenesis...
  61. doi Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas
    David J Stewart
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:3881-8. 2009
    ..By hypomethylating genes, decitabine may up-regulate factors required for chemotherapeutic cytotoxicity. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1...
  62. ncbi Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry
    Jie Shen
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:11194-206. 2006
    ..In addition, some of the proteins detected by this approach may be novel biomarkers for early detection of lung cancer and novel targets for chemoprevention or therapy...
  63. doi Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung
    Koji Tsuta
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Pathol Res Pract 208:470-4. 2012
    ..Except for SSTR5, all SSTRs showed a tendency toward decreased expression in well- to poorly differentiated NECs. We believe that these findings indicate important implications for the future of SST analog therapy...
  64. ncbi Cystic bronchioloalveolar cell carcinoma
    Bradley S Sabloff
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Imaging 20:110-4. 2005
    ..Knowledge of the spectrum of radiologic manifestations of BAC and correlation with clinical history are important in suggesting the diagnosis and preventing misinterpretation...
  65. doi Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas
    Koji Tsuta
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 136:252-9. 2011
    ..4 was the best threshold for differentiating ACs from TCs. These values correspond to 4/10 hpf and 10/10 hpf. We showed that the PHH3-based mitosis-counting method is a reliable, easy method for counting mitoses in pulmonary NECs...
  66. pmc ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion
    Weiwen Long
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Invest 122:1869-80. 2012
    ..As such, ERK3 protein kinase may be an attractive target for therapeutic treatment of invasive lung cancer...
  67. doi Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung
    Koji Tsuta
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Histopathology 59:526-36. 2011
    ..Aims: To analyse the clinicopathological features and immunohistchemical profile of spindle-cell carcinoid tumours (SCCT) of the lung...
  68. doi Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases
    Koji Tsuta
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 42:578-85. 2011
    ..Although this variant does not differ in clinical features of nononcocytic neuroendocrine tumors, histologic features of the oncocytic neuroendocrine tumor can be a potential cause of diagnostic error...
  69. doi Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung
    Koji Tsuta
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Histopathology 58:276-85. 2011
    ..The aim of this study was to analyse the significance of sustentacular cells in pulmonary neuroendocrine carcinomas (NECs)...
  70. doi Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer Prev Res (Phila) 4:779-82. 2011
    ..These results, along with closely related clinical results of the BATTLE program, support the promise of this cotargeting approach for lung cancer prevention and therapy and of cyclin D1 as a predictive, personalizing marker for it...
  71. pmc Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development
    Woo Young Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 69:7439-48. 2009
    ..Furthermore, the use of selective IGF-IR inhibitors may be a rational approach to controlling lung cancer...
  72. pmc Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer
    Lauren Averett Byers
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:1755-63. 2010
    ..In conclusion, serum CAF profiling, particularly in HPV-negative patients, may be useful for identifying those at highest risk for recurrence...
  73. doi Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
    ....
  74. pmc The BATTLE to personalize lung cancer prevention through reverse migration
    Kathryn A Gold
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 4:962-72. 2011
    ....
  75. ncbi Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer
    Jian Gu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:7329-38. 2006
    ..The aim of this study was to investigate the prognostic value of hypermethylation of tumor suppressor genes in patients with non-small cell lung cancer (NSCLC)...
  76. ncbi Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:3279-87. 2005
    ..To review recent advances in pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC)...
  77. ncbi Genetics of preneoplasia: lessons from lung cancer
    Ignacio I Wistuba
    Department of Pathology and Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Mol Med 7:3-14. 2007
    ..f) Finally, the identification of deregulated molecular signaling pathways in lung cancer preneoplasias may provide a rationale for designing novel strategies for early detection and targeted chemoprevention of lung cancer...
  78. ncbi Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
    Ludmila Prudkin
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Ann Diagn Pathol 10:306-15. 2006
    ..Importantly, the findings of EGFR abnormalities in lung cancer have supported the notion that different molecular mechanisms and pathways are involved in the pathogenesis of lung cancer arising in never and ever smokers...
  79. pmc Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers
    Kristy L Richards
    Department of Genetics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:606-17. 2011
    ....
  80. doi Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma
    Doina Ivan
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Cutan Pathol 37:231-6. 2010
    ....
  81. doi Methodological and practical challenges for personalized cancer therapies
    Ignacio I Wistuba
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:135-41. 2011
    ..These challenges include limitations of current biomarker development methodologies and regulatory and reimbursement policies and practices...
  82. doi Molecular pathology of thymic epithelial neoplasms
    Elisabetta Kuhn
    Department of Pathology Unit 85, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Hematol Oncol Clin North Am 22:443-55. 2008
    ..However, this progress is still limited and has not led to better tumor classifications, prognostication of outcome, and design of molecular targeted therapy...
  83. ncbi Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway
    Dianren Xia
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    J Biol Chem 282:3507-19. 2007
    ..Thus, MKK4 promotes cell survival by activating phosphatidylinositol 3-kinase through an NFkappaB/PTEN-dependent pathway...
  84. pmc HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer
    Toru Kawamoto
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX
    Gastrointest Cancer Res 1:221-7. 2007
    ..Tumor specimens from patients from the United States and Chile were examined for expression of HER-2/neu, EGFR, and their activated forms (p-erbB2, p-EGFR)...
  85. ncbi Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response
    Bradley S Sabloff
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 6:108-12. 2004
    ..Other imaging modalities, such as positron emission tomography scanning, may prove helpful in assessing the metabolic response to therapy but have yet to be proven effective...
  86. ncbi Gallbladder cancer: lessons from a rare tumour
    Ignacio I Wistuba
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Rev Cancer 4:695-706. 2004
    ..An understanding of how these risk factors contribute to the molecular basis of the disease is essential for understanding the origins of this unusual cancer...
  87. ncbi Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells
    Ximing Tang
    Molecular Biology Laboratory, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Unit 432, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Res 2:685-91. 2004
    ..These results suggest that DAP kinase is involved in TRAIL-mediated cell apoptosis and that a demethylating agent may have a role in enhancing TRAIL-mediated apoptosis in some NSCLC cells by reactivation of DAP kinase...
  88. ncbi Histologic evaluation of bronchial squamous lesions: any role in lung cancer risk assessment?
    Ignacio I Wistuba
    Clin Cancer Res 11:1358-60. 2005
  89. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
    ..However, the role of such mutations in the pathogenesis of lung cancers is unclear...
  90. ncbi Characteristic genetic alterations in lung cancer
    Ignacio I Wistuba
    Department of Pathology, Pontificia Universidad Catolica de Chile, Santiago, Chile
    Methods Mol Med 74:3-28. 2003
    ....
  91. ncbi Smoking molecular damage in bronchial epithelium
    Ignacio I Wistuba
    Department of Anatomic Pathology, Pontificia Universidad Catolica de Chile, Santiago, P O Box 114 D, Chile
    Oncogene 21:7298-306. 2002
    ....
  92. pmc Application of a methylation gene panel by quantitative PCR for lung cancers
    Narayan Shivapurkar
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Cancer Lett 247:56-71. 2007
    ..Our preliminary data on the analysis of sputum DNA specimens from cancer patients further support these observations...
  93. ncbi Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    Cancer Res 65:1642-6. 2005
    ..EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers...
  94. pmc Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
    Masaharu Nomura
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS Med 4:e125. 2007
    ..The objective of this study was to examine distributions of these three polymorphisms and their relationships to each other and to EGFR gene mutations and allelic imbalance (AI) in non-small cell lung cancers...
  95. ncbi Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures
    Shinichi Toyooka
    Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    Clin Cancer Res 8:2292-7. 2002
    ..Because loss of heterozygosity at 8p21-22 is a frequent event in lung cancers, we studied FEZ1 alteration in short-term cultures of resected lung cancer tumors and cell lines...
  96. ncbi Clonality of combined tumors
    Jiaoti Huang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Arch Pathol Lab Med 126:437-41. 2002
    ..Tumors with mixed morphologic patterns (combined tumors) are sometimes encountered, and questions often arise regarding the mechanism of molecular pathogenesis of each component and their relationships...
  97. pmc Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer
    Yanan Yang
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 3:e2220. 2008
    ..The signals activated by oncogenic K-ras that mediate BASC expansion have not been fully defined...
  98. ncbi The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Okayama University, Okayama, Japan
    Clin Cancer Res 13:5763-8. 2007
    ..In this study, we extensively investigated the impact of sex and smoking on the EGFR mutation...
  99. pmc Somatic mutations affect key pathways in lung adenocarcinoma
    Li Ding
    The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Nature 455:1069-75. 2008
    ..Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment...
  100. ncbi Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer
    Michael G House
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Ann Surg Oncol 10:882-9. 2003
    ..Aberrant methylation of tumor-suppressor genes is associated with a loss of gene function that can afford selective growth advantages to sporadic neoplastic cells arising during gallbladder inflammation...
  101. ncbi Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma
    Erick Riquelme
    Department of Anatomic Pathology, Pontificia Universidad Catolica de Chile, 85 Lira St Santiago 133202, Chile
    Cancer Lett 250:100-6. 2007
    ..We conclude that epigenetic inactivation by abnormal promoter methylation is a frequent event in chromosome 3p candidate TSGs in GBC pathogenesis, especially affecting genes SEMA3B (3p21.3) and FHIT (3p14.2)...